Combining CSPG4-CAR and CD20-CCR for treatment of metastatic melanoma

The prognosis for patients with metastatic melanoma is poor and treatment options are limited. Genetically-engineered T cell therapy targeting chondroitin sulfate proteoglycan 4 (CSPG4), however, represents a promising treatment option, especially as both primary melanoma cells as well as metastases...

Celý popis

Podrobná bibliografia

Vydané v:	Frontiers in immunology Ročník 14; s. 1178060
Hlavní autori:	Teppert, Karin, Winter, Nora, Herbel, Vera, Brandes, Caroline, Lennartz, Simon, Engert, Fabian, Kaiser, Andrew, Schaser, Thomas, Lock, Dominik
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Frontiers Media S.A 11.10.2023
Predmet:	adoptive T cell therapy chimeric antigen receptor chimeric costimulatory receptor Immunology immunotherapy melanoma
ISSN:	1664-3224, 1664-3224
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!